Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial

被引：0
|
作者：
Venerito, Marino [1 ]
Abou-Alfa, G. K. [2 ]
Mollon, P. [3 ]
Meyer, T. [4 ]
Cheng, A. -L [5 ]
El-Khoueiry, A. B. [6 ]
Kelley, R. K. [7 ]
Baron, A. D. [8 ]
Benzaghou, F. [9 ]
Valcheva, V. [3 ]
Hazra, S. [10 ]
Mangeshkar, M. [10 ]
Freemantle, N. [4 ]
机构：
[1] Univ Klinikum Magdeburg, Magdeburg, Germany
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Ipsen Pharma SAS, Boulogne, France
[4] UCL, London, England
[5] Staatliche Univ Taiwan, Taipei, Taiwan
[6] Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[8] Calif Pacific Med Ctr, San Francisco, CA USA
[9] Ipsen Innovat, Les Ulis, France
[10] Exelixis Inc, San Francisco, CA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
174
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [41] Life years and quality-adjusted life years (QALYs) among people with diabetes
    Narayan, KM
    Boyle, J
    Thompson, T
    Sorensen, S
    Williamson, D
    DIABETES, 2003, 52 : A10 - A10
  • [42] ESTIMATING LIFE YEARS AND QUALITY-ADJUSTED LIFE YEARS IN HEAVILY TREATMENT-EXPERIENCED (HTE) PATIENTS
    McEwan, P.
    Darlington, O.
    van Doornewaard, A.
    Webster, S.
    Ward, T.
    Martin, A. A.
    Punekar, Y. S.
    VALUE IN HEALTH, 2017, 20 (09) : A790 - A790
  • [43] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 54 - 63
  • [44] Cabozantinib in the treatment of advanced hepatocellular carcinoma patients
    Klank-Sokolowska, Ewa
    Kucharewicz, Mariola
    Wojtukiewicz, Marek Z.
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (04): : 195 - 201
  • [45] Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
    Rimassa, Lorenza
    Kelley, Robin Kate
    Meyer, Tim
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Lim, Ho Yeong
    Tran, Albert
    Chan, Yi-Wah
    McAdam, Paul
    Wang, Evelyn
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    LIVER CANCER, 2021, : 38 - 47
  • [46] Outcomes based on plasma biomarkers for the Phase III CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Zekry, A.
    Rimassa, L.
    Kelley, R.
    Meyer, T.
    Ryoo, B.
    Merle, P.
    Park, J.
    Blanc, J.
    Lim, H.
    Tran, A.
    Borgman-Hagey, A.
    Clary, D.
    Wang, E.
    Cheng, A.
    El-Khoueiry, A.
    Abou-Alfa, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 41 - 42
  • [47] Quality of life and quality-adjusted life years after stroke in Sierra Leone
    Youkee, Daniel
    Deen, Gibrilla F.
    Sackley, Catherine
    Lisk, Durodami R.
    Marshall, Iain
    Soley-Bori, Marina
    INTERNATIONAL JOURNAL OF STROKE, 2024, 19 (09) : 981 - 988
  • [48] Health-Related Quality of Life, Quality-Adjusted Life Years, and Quality-Adjusted Life Expectancy in New York City from 1995 to 2006
    Lubetkin, Erica I.
    Jia, Haomiao
    JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2009, 86 (04): : 551 - 561
  • [49] Health-Related Quality of Life, Quality-Adjusted Life Years, and Quality-Adjusted Life Expectancy in New York City from 1995 to 2006
    Erica I. Lubetkin
    Haomiao Jia
    Journal of Urban Health, 2009, 86 : 551 - 561
  • [50] QUALITY OF LIFE (QOL) IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) IN CLINICAL TRIALS AND HEALTH TECHNOLOGY APPRAISAL (HTA) IMPLICATIONS
    Moon, J.
    Hurtado, P.
    Lucchino, M.
    Sathi, C.
    Vidalis, A.
    Demont, E.
    Gulotta, G.
    Dumoulin, O.
    VALUE IN HEALTH, 2022, 25 (07) : S572 - S572
12345